Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSWALK-a crovalimab study for acute uncomplicated vaso-occlusive episodes in sickle cell disease
PACTR202308825367505Phase 1Recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing Crovalimab with Placebo (2 arms). Primary endpoints: Percentage of participants with adverse events and Percentage of participants with infusion-related reactions and hypersensitivity. Started Mar 2022; status: recruiting.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202308825367505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202308825367505.